Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.
A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.
People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.
Hair loss treatment with Pyrilutamide, Minoxidil, and Finasteride showed improvement after 4 months. Shedding reduced, hair feels stronger and healthier, with no side effects.
PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.
PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.
PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.
The conversation discusses using cyproterone temporarily to reverse hair loss, followed by finasteride to maintain regrowth. Concerns about cyproterone's side effects, such as lowering testosterone and potential health risks, are raised, with alternatives like spironolactone suggested for androgen-related issues.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
A 40-year-old user reports promising hairline improvement after 4 months of using 1mg finasteride daily and 5% minoxidil foam 2-2.5 times daily. The hairline vellus hair appears to be turning terminal.
Eucapil is discussed as a potential hair loss treatment with some believing it to be effective, though its efficacy compared to finasteride is debated. It is considered an anti-androgen treatment, often used alongside other treatments like minoxidil and finasteride, but lacks independent studies to fully support its effectiveness.
The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.
Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.
PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.
The conversation is about someone's 4-month hair regrowth progress using 0.5mg dutasteride and topical minoxidil. Another person is inspired and is using 5mg finasteride and 5% minoxidil topically twice daily, hoping for similar results.
User sshamu's progress pictures of 4 months using minoxidil foam and 1MM dermarolling for hair loss, which resulted in impressive results. There is also discussion about how often to use the treatments, as well as potential side effects of finasteride.
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.
A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.
Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.
Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.
PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.
Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
The user shared a 4-month update on hair loss treatment using finasteride, minoxidil, and derma stamps, showing significant progress. The user experienced no side effects and plans to continue the treatment, updating monthly.
PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.